鉄過剰状態における造血幹細胞内鉄代謝制御の解明-アナモルシンを中心に-

2021 Fiscal Year Annual Research Report

• Project/Area Number: 19K08861
• Research Institution: Osaka University
• Principal Investigator: 柴山 浩彦 大阪大学, 医学系研究科, 招へい教授 (60346202)
• Co-Investigator(Kenkyū-buntansha): 野崎 健司 大阪大学, 医学部附属病院, 医員 (00836413) ; 横田 貴史 大阪大学, 医学系研究科, 准教授 (60403200)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: アナモルシン / 鉄・硫黄クラスター / アポトーシス / 遺伝子欠損マウス / 条件付き遺伝子欠損マウス / 造血幹細胞 / RNA-Seq / Bリンパ球

Outline of Annual Research Achievements

本研究では、申請者らがクローニングした鉄・硫黄クラスター形成に重要な役割を有する抗アポトーシス分子アナモルシン(AM)の造血幹細胞における機能と鉄過剰状態がAMの機能におよぼす影響についての解析をおこなっている。申請者らは、AMコンディショナルノックアウトマウス（AM flox/floxマウス）を作製することで、in vivoにおいて、種々の臓器、細胞のAMを欠損させることを可能としている。最初に、CD19-Cre TgマウスとAM flox/floxマウスを交配することで、CD19を発現するBリンパ球においてAMが欠損するマウスを作成した。その結果、脾臓におけるBリンパ球の最終分化段階である成熟Bリンパ球分画（FO-Ⅰ細胞）の著明な減少を認めた。それに伴い、末梢血やリンパ節のBリンパ球も著明に減少していることを確認した。また、脾臓におけるBリンパ球のアポトーシスが亢進していることも確認し、AMは抗アポトーシス作用によって、Bリンパ球の分化を制御していることが明らかとなった。Bリンパ球特異的AMKOマウスでは、FO-I細胞の減少に加え、脾臓のplasmablast様B細胞の減少や血清IgG3,IgMの減少といったBtk欠損マウスで報告されている特徴が見られていること、また、BCR-Btk pathwayの下流にあるp38MAPKの発現も低下していることから、BCR-Btk-p38MAPKシグナルの減弱が、B細胞特異的AMKOマウスにおけるFO-I細胞が減少する機序の一つと考えている。さらに、MX-Creリコンビナーゼトランスジェニック（MX-Cre-Tg）マウスとAM flox/floxマウスを交配した MX-Cre-Tg/AM flox/floxマウスの造血幹細胞に焦点をあてた研究をおこない、PIPCを投与することで、造血幹細胞のAMを欠損させるマウスを作成した。

Research Products

• [Journal Article] Impaired B cell terminal differentiation in B cell-specific knockout mice of cell death-defying factor anamorsin. (2022)
  • Author(s): Hamanaka Y, Tanimura A, Yokota T, Ezoe S, Ichii M, Nagate Y, Oritani K, Kanakura Y, Hosen N, Shibayama H.
  • Journal Title: Biochem Biophys Res Commun Volume: 603 Pages: 1-6
  • DOI: 10.1016/j.bbrc.2022.03.018.
  • Peer Reviewed
• [Journal Article] Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. (2022)
  • Author(s): Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, Usuki K, Shimoda K, Ito M, VanWart SA, Zagrijtschuk O, Qin A, Kawase H, Miyachi N, Sato T, Komatsu N, Kirito K.
  • Journal Title: Int J Hematol Volume: ー Pages: ー
  • DOI: 10.1007/s12185-022-03341-9.
  • Peer Reviewed
• [Journal Article] Two-year outcomes of tirabrutinib monotherapy in Waldenstoom's macroglobulinemia. (2022)
  • Author(s): Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H, Endo T, Terui Y, Iwaki N, Fukuhara N, Tatetsu H, Iida S, Ishikawa T, Iguchi D, Izutsu K.
  • Journal Title: Cancer Sci Volume: ー Pages: ー
  • DOI: 10.1111/cas.15344.
  • Peer Reviewed
• [Journal Article] Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report. (2022)
  • Author(s): Kubo T, Hino A, Fukushima K, Shimomura Y, Kurashige M, Kusakabe S, Nagate Y, Fujita J, Yokota T, Kato H, Shibayama H, Tanemura A, Hosen N.
  • Journal Title: Int J Hematol Volume: ー Pages: ー
  • DOI: 10.1007/s12185-022-03312-0.
  • Peer Reviewed
• [Journal Article] Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow up of the Japanese subgroup of the randomized ENESTnd trial. (2022)
  • Author(s): Nakamae H, Yamamoto M, Sakaida E, Kanda Y, Ohmine K, Ono T, Matsumura I, Ishikawa M, Aoki M, Maki A, Shibayama H.
  • Journal Title: Int J Hematol Volume: 115 Pages: 33-42
  • DOI: 10.1007/s12185-021-03216-5.
  • Peer Reviewed
• [Journal Article] Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum. (2021)
  • Author(s): Nakaya A, Shibayama H, Nakatani E, Shimura Y, Kosugi S, Tanaka H, Fuchida S, Kanda J, Uoshima N, Kaneko H, Imada K, Ohta K, Ito T, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S.
  • Journal Title: eJHaem Volume: 2 Pages: 765-773
  • Peer Reviewed
• [Journal Article] A forodesine-based regimen as a therapeutic option for PTCL-NOS with Central nervous system involvement. (2021)
  • Author(s): Doi Y, Yokota T, Shibayama H, Matsumoto K, Kurashige M, Nozaki K, Fujita J, Fukushima K, Hosen N.
  • Journal Title: Leuk Lymphoma Volume: 63 Pages: 1013-1015
  • DOI: 10.1080/10428194.2021.2005043.
  • Peer Reviewed
• [Journal Article] Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial (2021)
  • Author(s): Murai K, Ureshino H, Kumagai T, Tanaka H, Nishiwaki K, Wakita S, Inokuchi K, Fukushima T, Yoshida C, Uoshima N, Kiguchi T, Mita M, Aoki J, Kimura S, Karimata K, Usuki K, Shimono J, Chinen Y, Kuroda J, Matsuda Y, Nakao K, Ono T, Fujimaki K, Shibayama H, Sakamoto J, Kimura S.
  • Journal Title: Lancet Haematol Volume: 8 Pages: e902-e911
  • DOI: 10.1016/S2352-3026(21)00333-1.
  • Peer Reviewed
• [Journal Article] Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial. (2021)
  • Author(s): Suzuki K, Min CK, Kim K, Lee JJ, Shibayama H, Ko PS, Huang SY, Li SS, Ding B, Khurana M, Iida S.
  • Journal Title: Int J Hematol Volume: 114 Pages: 653-663
  • DOI: 10.1007/s12185-021-03204-9.
  • Peer Reviewed
• [Journal Article] Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. (2021)
  • Author(s): Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Hojo S, Nakanishi T, Rai S.
  • Journal Title: Cancer Sci Volume: 112 Pages: 3627-3635
  • DOI: 10.1111/cas.15040.
  • Peer Reviewed
• [Journal Article] A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. (2021)
  • Author(s): Terui Y, Rai S, Izutsu K, Yamaguchi M, Takizawa J, Kuroda J, Ishikawa T, Kato K, Suehiro Y, Fukuhara N, Ohmine K, Goto H, Yamamoto K, Kanemura N, Ueda Y, Ishizawa K, Kumagai K, Kawasaki A, Saito T, Hashizume M, Shibayama H.
  • Journal Title: Cancer Sci Volume: 112 Pages: 2845-2854
  • DOI: 10.1111/cas.14937.
  • Peer Reviewed
• [Journal Article] Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden. (2021)
  • Author(s): Nozaki K, Sugahara H, Ueda S, Ishikawa J, Karasuno T, Iida M, Kamae T, Moriyama Y, Kawakami M, Kosugi S, Nakagawa M, Azenishi Y, Sakaniwa R, Kitamura T, Shibayama H.
  • Journal Title: Int J Hematol Volume: 114 Pages: 217-221
  • DOI: 10.1007/s12185-021-03151-5.
  • Peer Reviewed
• [Journal Article] Identification of CXCL12-abundant reticular cells in human adult bone marrow. (2021)
  • Author(s): Aoki K, Kurashige M, Ichii M, Higaki K, Sugiyama T, Kaito T, Ando W, Sugano N, Sakai T, Shibayama H; HANDAI Clinical Blood Club, Takaori-Kondo A, Morii E, Kanakura Y, Nagasawa T.
  • Journal Title: Br J Haematol Volume: 193 Pages: 659-668
  • DOI: 10.1111/bjh.17396.
  • Peer Reviewed
• [Journal Article] High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder. (2021)
  • Author(s): Saito H, Miyoshi H, Shibayama H, Toda J, Kusakabe S, Ichii M, Fujita J, Fukushima K, Maeda T, Mizuki M, Oritani K, Seto M, Yokota T, Kanakura Y, Hosen N, Ohshima K.
  • Journal Title: Int J Hematol Volume: 114 Pages: 53-64
  • DOI: 10.1007/s12185-021-03129-3.
  • Peer Reviewed
• [Journal Article] Oral ixazomib, lenalidomide, and dexamethasone for newly diagnosed transplant-ineligible multiple myeloma patients. (2021)
  • Author(s): Facon T, Venner CP, Bahlis NJ, Offner F, White D, Karlin L, Benboubker L, Rigaudeau S, Rodon P, Voog E, Yoon SS, Suzuki K, Shibayama H, Zhang X, Twumasi-Ankrah P, Yung G, Rifkin RM, Moreau P, Lonial S, Kumar SK, Richardson PG, Rajkumar SV.
  • Journal Title: Blood Volume: 137 Pages: 3616-3628
  • DOI: 10.1182/blood.2020008787.
  • Peer Reviewed
• [Journal Article] Safety and Antitumor Activity of Acalabrutinib for Relapsed/Refractory B-cell Malignancies: A Japanese Phase I Study. (2021)
  • Author(s): Izutsu K, Ando K, Ennishi D, Shibayama H, Suzumiya J, Yamamoto K, Ichikawa S, Kato K, Kumagai K, Patel P, Iizumi S, Hayashi N, Kawasumi H, Murayama K, Nagai H.
  • Journal Title: Cancer Sci Volume: 112 Pages: 2405-2415
  • DOI: 10.1111/cas.14886.
  • Peer Reviewed
• [Journal Article] Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma. (2021)
  • Author(s): Takakuwa T, Ohta K, Nakatani E, Ito T, Kaneko H, Fuchida SI, Shimura Y, Yagi H, Shibayama H, Kanda J, Uchiyama H, Kosugi S, Tanaka H, Kawata E, Uoshima N, Ishikawa J, Shibano M, Karasuno T, Shindo M, Shimizu Y, Imada K, Kanakura Y, Kuroda J, Hino M, Nomura S, Takaori-Kondo A, Shimazaki C, Matsumura I.
  • Journal Title: Hematol Oncol Volume: 39 Pages: 349-357
  • DOI: 10.1002/hon.2863.
  • Peer Reviewed
• [Journal Article] Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease. (2021)
  • Author(s): Konishi T, Kusakabe S, Hino A, Inamoto K, Yoshifuji K, Kiridoshi Y, Takeshita K, Sasajima S, Toya T, Igarashi A, Najima Y, Kobayashi T, Doki N, Motooka D, Nakamura S, Suyama M, Suda W, Shiota A, Atarashi K, Hattori M, Honda K, Yokota T, Ohashi K, Shibayama H, Fukushima K, Kakihana K.
  • Journal Title: Bone Marrow Transplant Volume: 56 Pages: 1728-1731
  • DOI: 10.1038/s41409-021-01249-2.
  • Peer Reviewed
• [Journal Article] Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance. (2021)
  • Author(s): Nozaki K, Fujioka Y, Sugiyama D, Ishikawa J, Iida M, Shibata M, Kosugi S, Nishikawa H, Shibayama H.
  • Journal Title: Int J Hematol Volume: 113 Pages: 772-774
  • DOI: 10.1007/s12185-021-03093-y.
  • Peer Reviewed
• [Journal Article] Autonomous TGFβ signaling induces phenotypic variation in human acute myeloid leukemia. (2021)
  • Author(s): Shingai Y, Yokota T, Okuzaki D, Sudo T, Ishibashi T, Doi Y, Ueda T, Ozawa T, Nakai R, Tanimura A, Ichii M, Shibayama H, Kanakura Y, Hosen N.
  • Journal Title: Stem Cells Volume: 39 Pages: 723-736
  • DOI: 10.1002/stem.3348.
  • Peer Reviewed
• [Journal Article] Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. (2021)
  • Author(s): Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S.
  • Journal Title: Eur J Haematol Volume: 106 Pages: 555-562
  • DOI: 10.1111/ejh.13586.
  • Peer Reviewed
• [Journal Article] Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: a prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. (2021)
  • Author(s): Hutchings M, Radford J, Ansell SM, Sureda A, Connors JM, Shibayama H, Abramson JS, Chua NS, Friedberg JW, LaCasce AS, Molina L, Engley G, Fenton K, Jolin H, Liu R, Gautam A, Gallamini A.
  • Journal Title: Hematol Oncol Volume: 39 Pages: 185-195
  • DOI: 10.1002/hon.2838.
  • Peer Reviewed
• [Presentation] Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01 (2021)
  • Author(s): Kentaro Fukushima, Hirohiko Shibayama, SungGi Chi, Naoko Hosono, Takahiro Yamauchi, Seiichiro Katagiri, Akihiko Gotoh, Makoto Yoshimitsu, Kenji Ishitsuka, Takaaki Ono, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinori Nakamura, Suguru Fukuhara, Koji Izutsu, Nobuhiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: The American Society of Hematology 63rd Annual Meeting
  • Int'l Joint Research
• [Presentation] Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial (2021)
  • Author(s): Takashi Kumagai, Kazunori Murai, Hiroshi Ureshino, Hideo Tanaka, Takaaki Ono, Katsumichi Fujimaki, Hirohiko Shibayama, Chisaki Mizumoto, Tomoharu Takeoka, Katsuhiro Io, Takeshi Kondo, Masatomo Miura, Yosuke Minami, Takayuki Ikezoe, Jun Imagawa, Ayako Takamori, Atsushi Kawaguchi, Junichi Sakamoto, Shinya Kimura
  • Organizer: The American Society of Hematology 63rd Annual Meeting
  • Int'l Joint Research
• [Presentation] Two-year follow-up data of Phase II study of Tirabrutinib, a second-generation bruton’s tyrosine kinase inhibitor, in patients with treatment-naive or relapsed/refractory Waldenstrom’s macroglobulinemia. (2021)
  • Author(s): Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu
  • Organizer: The American Society of Hematology 63rd Annual Meeting
  • Int'l Joint Research
• [Presentation] Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial (2021)
  • Author(s): Paul G. Richardson, Thierry Facon, Sophie Rigaudeau, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Arun Kumar, Philip Twumasi-Ankrah, Richard Labotka, Robert M. Rifkin, Sagar Lonial, Shaji K Kumar, S. Vincent Rajkumar, Philippe Moreau
  • Organizer: The American Society of Hematology 63rd Annual Meeting
  • Int'l Joint Research
• [Presentation] Genomic analysis of TP53 mutations in a multicenter NGS study of AML: HM-SCREEN-Japan01. (2021)
  • Author(s): Kentaro Fukushima, SunGi Chi, Hirohiko Shibayama, Nohoko Hosono, Takahiro Yamauchi, Seiichiro Katagiri, Akihiko Gotoh, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinobu Nakamura, Suguru Fukuhara, Koji Izutsu, Hirohiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Very elderly patients with myeloma: a multicenter retrospective analysis from Kansai Myeloma forum. (2021)
  • Author(s): Yusuke Okayama, Teruhito Takakuwa, Yuji Shimura, Nobuhiko Uoshima, Satoshi Yoshihara, Junya Kanda, Hirohiko Shibayama, Kentaro Fukushima, Kensuke Ota, Hideo Yagi, Shosaku Nomura, Chihiro Shimazaki, Itaru Matsumura, Akifumi Takaori, Naoki Hosen, Masayuki Hino, Junya Kuroda
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Nobel web application predicting patient-specific prognosis in MM from KMF using machine learning. (2021)
  • Author(s): Teruhito Takakuwa, Hiroshi Okamura, Shin-ichi Fuchida, Yuji Shimura, Junya Kanda, Nobuhiko Uoshima, Hirohiko Shibayama, Satoshi Yoshihara, Hideo Yagi, Masayuki Hino, Yuzuru Kanakura, Junya Kuroda, Akifumi Takaori, Chihiro Shimazaki, Itaru Matsumura, Shosaku Nomura
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Efficacy of elotuzumab plus lenalidomide and dexamethasone for MM: A retrospective analysis from KMF. (2021)
  • Author(s): Shin-ichi Fuchida, Tomoki Ito, Kensuke Ota, Hirohiko Shibayama, Kentaro Fukushima, Hirokazu Tanaka, Yuji Shimura, Kazunori Imada, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Naoki Hosen, Akifumi Takaori, Itaru Matsumura, Shosaku Nomura, Chihiro Shimazaki, Junya Kuroda
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Using ImmunoFISH to determine lymphoid neoplasm relapse after sex-mismatched HSCT or PTLD occurrence (2021)
  • Author(s): Ryumei Kurashige, Masako Kurashige, Yosuke Okada, Kohei Higuchi, Akihisa Hino, Takako Miyamura, Michiko Ichii, Kentaro Fukushima, Makoto Takeuchi, Akihisa Sawada, Masami Inoue, Hirohiko Shibayama, Eiichi Morii, Naoki Hosen
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] A Phase 2b study of an oral HDAC inhibitor HBI-8000 in patients with relapsed or refractory ATL (2021)
  • Author(s): Tatsuro Jo, Atae Utsunomiya, Koji Izutsu, Hirohiko Shibayama, Kazuya Shimoda, Yasushi Takamatsu, Kuniko Takano, Kunihiro Tsukasaki, Jun Taguchi, Kentaro Yonekura, Shinichi Makita, Mireille Gillings, Hiroshi Onogi, Kensei Tobinai
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Genomic analysis of relapsed AML with RUNX1-RUNX1T1 in a comprehensive NGS multicenter study of AML (2021)
  • Author(s): Seiichiro Katagiri, Daigo Akabane, Akihiko Gotoh, SunGi Chi, Kentaro Fukushima, Hirohiko Shibayama, Naoko Hosono, Takahiro Yamauchi, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinobu Nakamura, Koji Izutsu, Hirohiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Genetic features of AML with MLL-rearrangement and NPM1 mutation: HM-SCREEN-JAPAN01 (2021)
  • Author(s): SunGi Chi, Kentaro Fukushima, Hirohiko Shibayama, Naoko Hosono, Takahiro Yamauchi, Seiichiro Katagiri, Akihiko Gotoh, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinobu Nakamura, Suguru Fukuhara, Koji Izutsu, Hirohiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Genetic features of AML with normal karyotype: HM-SCREEN-JAPAN01 (2021)
  • Author(s): SunGi Chi, Masamitsu Yanada, Kazuhito Yamamoto, Naoko Hosono, Takahiro Yamauchi, Kentaro Fukushima, Hirohiko Shibayama, Seiichiro Katagiri, Akihiko Gotoh, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinobu Nakamura, Suguru Fukuhara, Koji Izutsu, Hirohiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Genetic features of AML with IDH1/IDH2 mutation: HM-SCREEN-JAPAN01 (2021)
  • Author(s): Hirotaka Nakamura, SunGi Chi, Kentaro Fukushima, Hirohiko Shibayama, Naoko Hosono, Takahiro Yamauchi, Seiichiro Katagiri, Akihiko Gotoh, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinobu Nakamura, Suguru Fukuhara, Koji Izutsu, Hirohiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] A mutation profiling multicenter study of patients with AML: HM-SCREEN-JAPAN01 (2021)
  • Author(s): Naoko Hosono, Takahiro Yamauchi, SunGi Chi, Kentaro Fukushima, Hirohiko Shibayama, Seiichiro Katagiri, Akihiko Gotoh, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinobu Nakamura, Suguru Fukuhara, Koji Izutsu, Hirohiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] A case of PTCL-NOS with central nervous system involvement successfully treated with oral forodesine. (2021)
  • Author(s): Yukio Doi, Takafumi Yokota, Hirohiko Shibayama, Kana Matsumoto, Masako Kurashige, Kenji Nozaki, Kouki Yoshida, Makiko Suga, Midori Koike, Jun Toda, Keigo Akuta, Akihisa Hino, Tomoaki Ueda, Yasuhiro Nagate, Jiro Fujita, Kentaro Fukushima, Naoki Hosen
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] A Phase 2b study of an oral HDAC inhibitor HBI-8000 in patients with relapsed or refractory PTCL (2021)
  • Author(s): Hidetsugu Kawai, Jun Ando, Ilseung Choi, Junya Kuroda, Mitsutoshi Kurosawa, Hong Ghi Lee, Jae Hoon Lee, Won Sik Lee, Hironobu Minami, Hirokazu Nagai, Hirohiko Shibayama, Takeo Shindo, Kenji Tsukamoto, Kunihiro Tsukasaki, Toshiki Uchida, Shinya Rai, Deok Hwan Yang, Shinichiro Yoshida, Mireille Gillings, Kensei Tobinai
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Genetic features of AML requiring hematopoietic stem cell transplantation: HM-SCREEN-JAPAN01 (2021)
  • Author(s): Motoki Eguchi, Takanobu Morishita, SunGi Chi, Kentaro Fukushima, Hirohiko Shibayama, Naoko Hosono, Takahiro Yamauchi, Seiichiro Katagiri, Akihiko Gotoh, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinobu Nakamura, Suguru Fukuhara, Koji Izutsu, Hirohiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: 第83回日本血液学会学術集会
• [Presentation] Clinical significance of FLT3 mutations in a NGS multicenter study of AML: HM-SCREEN-JAPAN01 (2021)
  • Author(s): Kentaro Fukushima, Hirohiko Shibayama, SunGi Chi, Nohoko Hosono, Takahiro Yamauchi, Seiichiro Katagiri, Akihiko Gotoh, Naoto Takahashi, Satoshi Iyama, Makoto Nakamura, Yukinobu Nakamura, Suguru Fukuhara, Koji Izutsu, Hirohiko Yamauchi, Junichiro Yuda, Yosuke Minami
  • Organizer: 第83回日本血液学会学術集会